Hormonal
Tirzepatide 10mg and 15mg doses are associated with significantly higher rates of discontinuation due to adverse events compared to GLP-1 receptor agonists, primarily driven by gastrointestinal adverse events.
If you are using Tirzepatide at 10mg or 15mg, be aware that you are more likely to stop the medication due to side effects (like nausea or diarrhea) compared to using other GLP-1 drugs like semaglutide or dulaglutide. This risk is dose-dependent. If side effects become intolerable, discuss dose reduction or switching with your provider.
Compared with GLP-1 RAs, more participants receiving TZP 10 mg (pooled RR=1.75, 95%CI [1.16-2.63], P=0.007) and 15mg (pooled RR=2.03, 95%CI [1.37-3.01], P=0.0004) experienced the discontinuation
Why this rating
Based on a systematic review of 9 RCTs with nearly 10,000 patients, though heterogeneity and publication bias are noted.
Source
A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
Zhuqing Meng et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1121387
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →